Tirzepatide Cost Without Insurance: All Pricing Options

You have researched tirzepatide. You know you want to talk with a provider about it. Now you are figuring out what it will cost out of pocket if you do not have insurance or your insurance will not cover it. Here is how tirzepatide pricing is structured for both brand-name and compounded options, and how to compare the real total.

Brand-name tirzepatide without insurance

Brand-name tirzepatide is made by Eli Lilly and Company and sold under two names: Zepbound, approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity, and Mounjaro, approved for type 2 diabetes.^[1][2] As of October 2026, Drugs@FDA lists no FDA-approved generic tirzepatide.^[3]

Without insurance, there are two main ways to pay for the brand-name product:

• The pharmacy’s cash price. This is based on the manufacturer’s list price, and it is what you pay if you fill a prescription at a retail pharmacy with no coverage or discount.
• The manufacturer’s self-pay program. Eli Lilly sells some Zepbound presentations directly to self-pay patients through LillyDirect, often at a lower price than the retail cash price. What is offered, and at what price, can differ by form (pen or vial) and dose.^[4]

The exact price depends on:

• Which product and form you are prescribed (pen or vial)
• The dose strength. Zepbound comes in six strengths, from 2.5mg to 15mg, and the label starts at 2.5mg weekly and steps up in 2.5mg increments, so your dose usually rises during the first months.^[1]
• Your pharmacy and location
• Whether you qualify for a manufacturer savings card (generally for people with commercial insurance) or a patient assistance program, each with its own eligibility rules

Prices change, so check the manufacturer’s current pricing page and ask your pharmacy for its cash price before you fill. Our guide to brand-name GLP-1 self-pay programs explains how these programs work.

The medication price does not include provider visit fees, which may be separate if you see a private practice provider. Telehealth programs sometimes bundle visits into a membership fee.

Compounded tirzepatide pricing

Compounded tirzepatide is prepared by a pharmacy and sold through telehealth programs and some local practices, each of which sets its own price. There is no single price, and the way programs structure it varies widely:

• Flat monthly price. Some programs charge the same monthly amount regardless of dose.
• Per-dose pricing. Others price by dose tier, so the monthly cost rises as your dose goes up.
• Bundled or separate fees. Some programs bundle the medication, provider visits, and shipping into one price. Others bill the membership, medication, labs, and shipping separately.

Some programs describe their price as “all-inclusive,” but there is no standard definition. One program may include provider visits, labs, and shipping; another may leave out labs, dose increases, or follow-up visits. Before you sign up, ask the program to list what the price covers and what costs extra.

Compare the total cost, not the headline number: medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms. Prices vary by program and dose and change often, so confirm the current price with any provider you are considering.

Cost comparison: brand-name vs. compounded

The cost difference reflects how each product is made, regulated, and sold, not clinical equivalence. Brand-name tirzepatide is manufactured by a pharmaceutical company under proprietary processes, approved by the FDA, and priced to recover research, development, and regulatory costs. Compounded tirzepatide is prepared by a licensed pharmacy and has not undergone FDA review for safety, effectiveness, or quality.

Both require a prescription from a licensed provider and a medical evaluation. But they are different products with different regulatory histories. Transformation Health does not accept payment from providers. How we make money.

Why brand-name tirzepatide costs so much

Brand-name tirzepatide carries costs that compounded versions do not:

Patent protection. Tirzepatide is protected by patents held by its manufacturer, and no FDA-approved generic exists.^[3] Until generics are approved and launched, the manufacturer has exclusive control of the market and sets prices accordingly.

FDA approval and R&D investment. Bringing a new drug to FDA approval requires a large investment in clinical trials, safety testing, manufacturing validation, and regulatory submissions. These costs are recouped through pricing while the drug is under patent protection.

Manufacturing and supply chain. Brand-name pharmaceuticals are manufactured at scale in FDA-inspected facilities with documented quality control at every step. That infrastructure costs more than pharmacy compounding.

Insurance reimbursement expectations. List prices are also set with insurance negotiations in mind. Insurers negotiate discounts, but people without insurance can end up paying the full list-based price at a retail pharmacy unless they use a manufacturer self-pay program or another discount.

What insurance typically covers (and does not)

Medicare Part D. Federal law lets drug plans exclude “agents when used for anorexia, weight loss, or weight gain,” and Medicare Part D carries that exclusion over, so Part D generally does not cover tirzepatide for weight loss alone.^[5][6] Plans may cover tirzepatide for other FDA-approved uses, such as type 2 diabetes, usually with plan rules such as prior authorization. CMS is also running a temporary program for some beneficiaries; see our guide to the Medicare GLP-1 Bridge.

Medicaid. Coverage varies significantly by state. Some state Medicaid programs cover GLP-1 medications for type 2 diabetes, and fewer cover them for weight management. Contact your state Medicaid office to find out whether tirzepatide is a covered benefit for your situation, and see our guide to the BALANCE model for Medicaid.

Commercial insurance. Some employer-sponsored health plans cover tirzepatide for type 2 diabetes. Fewer cover GLP-1 and GIP/GLP-1 medications for weight management, and coverage depends on the plan and the employer. Prior authorization requirements are common even when coverage exists.

The bottom line. If you have insurance, tirzepatide may be covered if you have type 2 diabetes, but coverage for weight management alone is not standard. Some people with insurance still pay out of pocket because of deductibles, copays, or prior authorization delays. Compare your plan’s cost with the self-pay and compounded options before you decide.

The compounded option: what to know

Compounded tirzepatide became widely available while tirzepatide was on the FDA’s drug shortage list, because shortage status lets compounding pharmacies prepare copies of an approved drug under certain conditions. As of October 2026, FDA’s drug shortage database lists the tirzepatide injection shortage as resolved.^[7] Pharmacies may still compound tirzepatide only in narrower circumstances under federal and state law, and FDA has said compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug.^[8][9]

Key points:

• Compounded tirzepatide is NOT FDA-approved. The FDA does not review it for safety, effectiveness, or quality. This is a meaningful distinction, not a technicality.
• Compounded tirzepatide is a distinct product from brand-name tirzepatide. Formulation, purity, and potency may differ.
• Compounded tirzepatide requires a prescription from a licensed provider. It is not available over the counter or without a medical evaluation.
• The rules for compounding can change when FDA or state regulators act, so availability is not guaranteed.

Compounded medications are prepared by licensed pharmacists under federal and state pharmacy compounding laws. But they operate under a different regulatory framework than brand-name medications and should not be considered FDA-approved drugs.

For a complete explanation of compounded tirzepatide, the regulatory framework, and quality standards, see: Compounded tirzepatide: what it is and what it costs.

What to check before using tirzepatide

Whether tirzepatide is appropriate is a clinical decision a licensed provider makes based on your health history, not a box you check.

FDA-approved use. Zepbound is approved, along with a reduced-calorie diet and increased physical activity, for adults with obesity, or adults with overweight and at least one weight-related condition. In the main trial that supported that approval, enrolled adults had a BMI of 30 or higher, or a BMI of 27 to 30 with at least one weight-related condition.^[1]

Weight-related health conditions include:

• High blood pressure (hypertension)
• Type 2 diabetes
• Heart disease
• Sleep apnea
• High cholesterol
• Other metabolic conditions

Medical evaluation. Even if your BMI meets the threshold, a provider should review your current medications, medical history, and any contraindications. The label says not to use tirzepatide if you or a family member has had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious allergic reaction to tirzepatide.^[1] Other medical situations can also make it inappropriate.

State rules. Some states require a live video visit before a first prescription can be written. If that applies where you live, the provider you choose will tell you.

Not everyone who asks will be prescribed tirzepatide, and that decision should come from a provider’s review, not from weight alone.

How to get started without insurance

At most telehealth programs, the process follows a path like this. The details vary by program and by provider.

Step 1: Share your health history. You answer questions about your health history, current medications, and weight, usually through the program’s online intake or a visit.

Step 2: Provider review. A licensed provider reviews your information and decides whether tirzepatide is clinically appropriate for you.

Step 3: Prescription and pharmacy. If the provider writes a prescription, a pharmacy fills it. Depending on the program, that may be a retail pharmacy, the manufacturer’s self-pay pharmacy, or a compounding pharmacy, and the medication may be shipped to you.

Step 4: Follow-up. The provider checks in on side effects, dose increases, and progress. How often that happens, and whether it costs extra, varies by program.

Paying out of pocket means no insurance paperwork or prior authorization, but it also means the full cost is yours. Ask each program what you will pay at each dose and what is included before you start.

FSA and HSA: how they work with tirzepatide

IRS Publication 502 lists prescribed medicines as qualified medical expenses, and it counts weight-loss treatment when it treats a specific diagnosed disease, such as obesity.^[10] Whether a specific purchase qualifies, and what documentation you need, is up to your plan administrator, so check with them before you pay.

What happens after you start

A licensed provider monitors your progress through follow-up visits and, when needed, lab work. If tirzepatide is working well for you, you may stay on it. If adjustments are needed, the provider works with you on the dose or considers alternatives.

Plan for the long term. Zepbound is approved to reduce excess body weight and maintain that reduction long term.^[1] In the SURMOUNT-4 trial, published in JAMA in 2024, people who switched from tirzepatide to placebo regained a substantial share of the weight they had lost over the following year, while those who continued treatment maintained their results on average.^[11] Some people step down to a lower dose, and some eventually stop, but stopping often leads to regain, so any change should be planned with your provider.

Weight loss is not guaranteed. Results vary based on starting weight, metabolism, adherence to the medication, diet, exercise, sleep, stress, and overall health. A provider can help you set realistic expectations based on your specific circumstances.

Next steps

If you do not have insurance or your insurance will not cover tirzepatide, compare the total cost of each path: the pharmacy cash price, the manufacturer’s self-pay program, and compounded programs, including dose increases, visits, labs, shipping, and cancellation terms.

Or explore other options:

• Comparing injectable weight loss costs compare tirzepatide to semaglutide and other choices
• Insurance coverage for weight loss medications determine whether your plan covers tirzepatide
• Compounded tirzepatide details full explanation of what compounded tirzepatide is and how it differs from brand-name versions

Citations

[1] U.S. Food and Drug Administration. “ZEPBOUND (tirzepatide) injection, prescribing information.” Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[2] U.S. Food and Drug Administration. “MOUNJARO (tirzepatide) injection, prescribing information.” Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf

[3] U.S. Food and Drug Administration. “Drugs@FDA: tirzepatide (NDA 217806, NDA 215866).” Accessed October 16, 2026. https://www.accessdata.fda.gov/scripts/cder/daf/

[4] Eli Lilly and Company. “LillyDirect.” Accessed October 16, 2026. https://www.lillydirect.com/

[5] 42 U.S.C. 1396r-8(d)(2)(A). https://www.law.cornell.edu/uscode/text/42/1396r-8

[6] 42 U.S.C. 1395w-102(e)(2)(A). https://www.law.cornell.edu/uscode/text/42/1395w-102

[7] U.S. Food and Drug Administration. “FDA Drug Shortages: Tirzepatide Injection.” Status: Resolved. Accessed October 16, 2026. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r

[8] U.S. Food and Drug Administration. “Human Drug Compounding Laws.” Content current as of 12/17/2024. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

[9] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

[10] Internal Revenue Service. “Publication 502: Medical and Dental Expenses.” https://www.irs.gov/publications/p502

[11] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/